Cyp3a4-Mediated in vitro Metabolism and in vivo Disposition of Lorlatinib in Rats
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s565228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Cong Xie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Lactams, Macrocyclic, Lactams. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
- Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Zitieren
APA
Xie, C., Guan, T., Huang, J., Chen, J., Li, Y., & Zheng, P. (2025). Cyp3a4-Mediated in vitro Metabolism and in vivo Disposition of Lorlatinib in Rats. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s565228
Vancouver
Xie C, Guan T, Huang J, Chen J, Li Y, Zheng P. Cyp3a4-Mediated in vitro Metabolism and in vivo Disposition of Lorlatinib in Rats. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s565228
BibTeX
@article{Xie2025,
author = {Xie, Cong and Guan, Tongshu and Huang, Jin and Chen, Jiayu and Li, Yilei and Zheng, Ping},
title = {Cyp3a4-Mediated in vitro Metabolism and in vivo Disposition of Lorlatinib in Rats},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s565228}
}
EUVIMED